FCF Life Sciences

We maximize the efficiency in fundraising processes
by integrating industry and finance expertise

Strategic Financing Advisory in Life Sciences

R&D-focused companies are in the DNA of FCF. Life Sciences is therefore a natural fit as one of our focus areas. Companies in this sector have unique financing requirements, which need to be addressed individually. For this reason, we have formed a team of highly specialized industry and finance experts to develop and execute the best individualized financing strategies for our Healthcare clients. The combined experience and skill set allows us to tackle every angle in the translation of a great technology into a sound financing story.

We work with innovative European Life Sciences companies with cutting-edge technologies from sectors such as:

  • Biotechnoloy
  • Medical Technology
  • Health Technology (IT)

We thrive to address all aspects of the financing challenges, that companies face from the seed to the commercialisation phase. We consider the long-term financing strategy as an important success factor, rather than focusing only on the next financing round. Part of this approach is to explore financing options on a regional and international scale and the combination of all available financing instruments:

  • Venture Capital
  • Equity-Linked Structures
  • Growth / Venture Debt
  • Off-Balance Financing
  • Licensing

FACTS & FIGURES

Experience
Over
100
years in aggregated Life Sciences experience
Leading Advisor Financing
Over
EUR 2bn
and 80 Life Sciences transactions aggregated
Contacts
Access to
>1.500
international investors
Team Professionals
Largest

European Life Sciences team specialised in pre-IPO financing

Research
8
regularly published Life Sciences reports

WHAT WE DO

At FCF Life Sciences, we develop bespoke financing strategies and support our clients throughout the entire fundraising process and beyond:

Industry Expertise

  • Technology Assessment
  • Finetuning of Equity Story
  • Pre Due-Diligence
  • Science-driven Deal Selection

Finance Expertise

  • Process Management
  • Investor Relations
  • Intelligent Market Monitoring
  • Efficient Investor Communications
Industry Expertise
  • Technology Assessment
  • Finetuning of Equity Story
  • Pre Due-Diligence
  • Science-driven Deal Selection
Finance Expertise
  • Process Management
  • Investor Relations
  • Intelligent Market Monitoring
  • Efficient Investor Communications

FOCUS AREAS

Equity

  • Actively managed global investor network to >1,500 investor
  • Highly customized investor approach based on a  proprietary investor data base
  • Focus on seed to crossover rounds


Debt

  • Most successful advisor in Europe
  • Direct access to the European Investment Bank with >EUR 200m raised
  • Access to more than 70 Growth / Venture Debt Providers (executive level)


China Licensing

  • Joint Venture with YAFO Capital (Shanghai) Ltd.
  • Specialist in fundraising, licensing and M&A transactions in the Asian market
  • Access to >500 financial and strategic investors

TEAM

We have built the largest venture stage dedicated team with industry and finance backgrounds in Europe:

Industry Expertise

Finance Expertise

We have built the largest venture stage dedicated team with industry and finance backgrounds in Europe:

Industry Expertise
Dr. Alexandra Goll
Advisor - Venture Capital
Dr. Axel Polack
Advisor - Science & Technology
Enno Spillner
Advisor - Capital Markets
Claus Schalper
Advisor - Corporate Affairs
Dr. Joachim M. Greuel
Advisor - Valuations
Prof. Dr. Horst Domdey
Advisor - Science & Technology
Finance Expertise
Dr. Mathias Schott
Head of Life Sciences
Arno Fuchs
Chief Executive Officer, FCF
Sebastian Sommer
Life Sciences Banking - Europe
Alexander Kuhn
Life Sciences Banking - Europe
Sean Jiang, CFA
Life Sciences Banking - China
Zaid Maleh
Life Sciences Banking - Dubai

GLOBAL NETWORK

We maintain trusted relationships to leading institutional and strategic Healthcare investors as well as family offices in Europe, USA and Asia. Supported by our US and Asian partners, we can approach the right investors depending on our client’s situation. We can rely on a deep network to Life Sciences specialists (e.g. legal, valuation, licensing and IPO investment banks in the USA and Europe) to execute a seamless 360-degree long-term financing strategy. Our goal is to create value by implementing the best financing options for our clients.

SELECTED TRANSACTIONS

Immunic AG

EIB Debt Facility
October 2020
€ 25 million
vasopharm_logo

Vasopharm GmbH

Transaction Support
July 2019
[amount confidential]
Logo_MP_AMW

AMW GmbH

EIB Debt Facility
November 2017
€ 25 million
numares transaction

numares AG

Capital Increase
November 2017
€ 11 million
MagForce

MagForce AG

EIB Debt Facility
August 2017
€ 35 million

Immunic AG

EIB Debt Facility
October 2020
€ 25 million

UPCOMING EVENT

MARKET INTELLIGENCE

We dedicate a fair amount of our resources to market monitoring, in order to derive market intelligence on life sciences companies, investors and capital market trends. We share our findings in various ways:

To hear from us on the latest market updates, please sign-up here:

Venture Capital Sentiment

Based on our market monitoring, we estimate the current monthly venture capital sentiment of the European biotechnology, medical technology and health technology sub-sectors:

August 2021:

Biotechnology

Medical Technology

Health Technology

Funding Volume (€m)
0
Trend
Funding Volume (€m)
0
Trend
Funding Volume (€m)
0
Trend

Biotechnology

Funding Volume (€m)
0
Trend

Medical Technology

Funding Volume (€m)
0
Trend

Health Technology

Funding Volume (€m)
0
Trend

Insights

We closely track the activity in the financial markets and are passionate about capital markets research. Not every idea or research question make it into the final selection for our publications. However, we generate interesting information on financing trends in Life Sciences sector, which we would like to share in our blog.

Capital Markets Research

We constantly engage in capital markets research to identify financing trends early in the Life Sciences sector. Our research focuses on the most relevant equity markets: Venture Capital, Public Equity, Initial Public Offerings (IPO). The findings are currently published in the following publications:

NEWS